![16 9 size People working in a lab](/sites/default/files/hk/en/2022-08/16%209%20size%20People%20working%20in%20a%20lab_0.jpg)
August 03, 2022
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
![CHMP_website_teaser_card_16_](/sites/default/files/hk/en/2022-06/CHMP_website_teaser_card_16_9.jpg)
June 28, 2022
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
![COVID-19研究中的治疗停止 COVID-19研究中的治疗停止](/sites/default/files/hk/en/2022-06/press-release-holding-image01.jpg)
June 23, 2022
Stop of treatment in COVID-19 study
![T cell](/sites/default/files/hk/en/2022-07/T-cell%201440_810.jpeg)
June 14, 2022
Option to Acquire Trutino Biosciences
![humbnail](/sites/default/files/hk/en/2022-07/thumbnail%281%29.jpg)
June 02, 2022
A*STAR antibodies bolster ADC and T-Cell engager development
![BI_PF_ATS_Press-Release_Social BI_PF_ATS_Press-Release_Social](/sites/default/files/hk/en/2022-07/786212706-002_BI_PF_ATS_Press-Release_Social_1920x1080_CC03_image-only_0.jpg)
May 15, 2022
Investigational treatment slowed lung function decline in IPF
![TwistPak TwistPak](/sites/default/files/hk/en/2022-07/TwistPak%20hero%20image.jpg)
May 12, 2022
TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility
![AI machine deep learning](/sites/default/files/hk/en/2022-08/AI%20machine%20deep%20learning.jpg)
May 11, 2022
Boehringer Ingelheim’s signal analytics technology is acquired by ArisGlobal
![048_© 2020, Peter Ginter - final adjustments at the “pipe crossover” resized](/sites/default/files/hk/en/2022-08/048_%C2%A9%202020%2C%20Peter%20Ginter%20-%20final%20adjustments%20at%20the%20%E2%80%9Cpipe%20crossover%E2%80%9D%20resized.jpeg)
April 05, 2022
Good business performance gives Boehringer Ingelheim tailwind for investment in Research and Development
![新的spesolimab数据显示GPP复发显著改善](/sites/default/files/hk/en/2022-06/AAD%20press%20release%20supporting%20image_resized.png)
March 28, 2022
New spesolimab data show significant improvement in GPP flares
![AAD press release](/sites/default/files/hk/en/2022-08/AAD%20press%20release%20supporting%20image_resized.jpeg)
March 28, 2022
New spesolimab data show clinically significant improvement in GPP flares
![勃林格殷格翰和世界Buiatrics协会支持反刍动物健康和福利的杰出研究 勃林格殷格翰和世界Buiatrics协会支持反刍动物健康和福利的杰出研究](/sites/default/files/hk/en/2022-06/_15A3705_0.jpg)
March 22, 2022
Boehringer Ingelheim and the World Association for Buiatrics support outstanding research on ruminant animal health and well-being
![220316_EMPA-KIDNEY_Early-Stop](/sites/default/files/hk/en/2022-08/220316_EMPA-KIDNEY_Early-Stop_0.jpg)
March 16, 2022
Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
![EMA_website_teaser_card_16_9](/sites/default/files/hk/en/2022-06/EMA_website_teaser_card_16_9.jpg)
March 07, 2022
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
Jardiance® (empagliflozin) becomes the first and only approved treatment in Europe for adults with symptomatic chronic heart failure regardless of ejection fraction
![EMPULSE_Image_2_Doctor_Patient](/sites/default/files/hk/en/2022-06/EMPULSE_Image_2_Doctor_Patient.jpg)
March 01, 2022
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
![FDA_website_teaser_card_16_9](/sites/default/files/hk/en/2022-06/FDA_website_teaser_card_16_9.jpg)
February 25, 2022
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
![786212575-009_BI_IPF_FDA Asset_1440X810_CC01-01 786212575-009_BI_IPF_FDA Asset_1440X810_CC01-01](/sites/default/files/hk/en/2022-06/786212575-009_BI_IPF_FDA%20Asset_1440X810_CC01-01.jpg)
February 24, 2022
FDA Grants BI 1015550 Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis
![test test](/sites/default/files/hk/en/2022-02/2-5.jpg)
February 16, 2022
Boehringer Ingelheim opens Health Management Centre in China
![black cow black cow](/sites/default/files/hk/en/2022-06/black%20cow%202.jpg)
February 09, 2022
New criteria for the susceptibility testing of Ubrolexin® when treating mastitis in dairy cows
![Mediapool_TopEmployer2022](/sites/default/files/hk/en/2022-08/Mediapool_TopEmployer2022%20%281%29.jpg)
January 20, 2022
Award: Boehringer Ingelheim is Global Top Employer 2022
![Immuno Immuno](/sites/default/files/hk/en/2022-09/400x400smallformat_Immuno.jpg)
January 18, 2022
Collaboration with MabGenesis to discover and develop novel monoclonal antibodies in canine
![勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值 勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值](/sites/default/files/hk/en/2022-06/400x400smallformat_Digital1.jpg)
January 03, 2022
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
![EMA验证了spesolimab在GPP中的上市许可申请](/sites/default/files/hk/en/2022-06/press-release-holding-image03_1.jpg)
December 29, 2021
EMA validates spesolimab marketing authorization application in GPP
![Spesolimab II期数据](/sites/default/files/hk/en/2022-06/Supporting%20press%20release%20image.png)
December 23, 2021
Spesolimab Phase II data
![美国FDA授予spesolimab在GPP中的优先审评](/sites/default/files/hk/en/2022-06/211213%20FDA%20Press%20Release%20Image_1440x810_72dpi_cc01.jpg)
December 15, 2021
U.S. FDA grants priority review for spesolimab in GPP
![勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值 勃林格殷格翰和Lifebit宣布合作捕获健康数据的转化价值](/sites/default/files/hk/en/2022-06/press-release-holding-image01_0.jpg)
December 10, 2021
Boehringer Ingelheim Launches University of Medicine Excellence
![Boehringer Ingelheim启动Boehringer Ingelheim Social Engagements Boehringer Ingelheim启动Boehringer Ingelheim Social Engagements](/sites/default/files/hk/en/2022-06/BISE_Bungoma_County%5B1%5D.jpg)
November 11, 2021
Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements
![共同创造更多健康2021: 为脆弱社区的5000万人创造可持续的健康解决办法 共同创造更多健康2021: 为脆弱社区的5000万人创造可持续的健康解决办法](/sites/default/files/hk/en/2022-06/MMHT_visual.jpg)
November 11, 2021
Making More Health Together 2021: Creating sustainable health solutions for 50 million people in vulnerable communities
![防腐肾亚组分析 press-release-holding-image02_1.jpg](/sites/default/files/hk/en/2022-06/press-release-holding-image02_1.jpg)
November 06, 2021
Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status
![勃林格殷格翰增加了对可持续发展的承诺, 通过社会创新影响5000万人 勃林格殷格翰增加了对可持续发展的承诺, 通过社会创新影响5000万人](/sites/default/files/hk/en/2022-06/More%2520Potential_Picture%2520for%2520Tweet%5B1%5D.jpg)
November 03, 2021
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
![Kachelbild SOL](/sites/default/files/hk/en/2022-06/Kachelbild%20SOL.jpeg)
October 27, 2021
科学与创新
![与伦敦大学国王学院的精神卫生合作](/sites/default/files/hk/en/2022-07/AdobeStock_KCL.jpeg)
October 27, 2021
Mental health collaboration with King’s College London
![尿素循环障碍治疗发展伙伴关系](/sites/default/files/hk/en/2022-07/cardpic.png)
October 26, 2021
Partnership to Develop Urea Cycle Disorders Therapy
![MIR_I_klein MIR_I_klein](/sites/default/files/hk/en/2022-06/MIR_I_klein_0.jpg)
October 25, 2021
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
![Aservo®EquiHaler®荣获2021年Pharmapack奖 Aservo®EquiHaler®荣获2021年Pharmapack奖](/sites/default/files/hk/en/2022-06/EquiHaler_001_2019-08-27_exhale_5790_0.jpg)
October 20, 2021
Aservo® EquiHaler® wins 2021 Pharmapack Award
![囊性纤维化基因治疗迈出下一步](/sites/default/files/hk/en/2022-07/AdobeStock_Woman_OxygenMask.jpeg)
October 19, 2021
Cystic Fibrosis Gene Therapy Takes to Next step
![img](/sites/default/files/hk/en/2022-07/BI%20TMA%20award%202021_3%20%28005%29%20%281%29_0.jpeg)
October 11, 2021
Boehringer Ingelheim awards its first Translational Medicine Award
![勃林格殷格翰将扩大法国新出现和跨界疾病的兽用疫苗接种能力 勃林格殷格翰将扩大法国新出现和跨界疾病的兽用疫苗接种能力](/sites/default/files/hk/en/2022-06/Lyon-Jonage%20.jpg)
October 08, 2021
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
![LSCC_Kachelbild](/sites/default/files/hk/en/2022-08/LSCC_Kachelbild.jpg)
October 06, 2021
Boehringer Ingelheim inaugurates biopharmaceutical production facility in Vienna, Austria
![世界狂犬病日:对抗狂犬病错误观念 世界狂犬病日:对抗狂犬病错误观念](/sites/default/files/hk/en/2022-06/WRD%20press%20release%20tile%20image%20option%202.png)
September 28, 2021
World Rabies Day: fighting rabies misconceptions
![Reserach and developmen Reserach and developmen](/sites/default/files/hk/en/2022-06/Reserach%20and%20development.png)
September 27, 2021
Boehringer Ingelheim and Invetx announce strategic collaboration
![2021 European PRRS Research Award winners 2021 European PRRS Research Award winners](/sites/default/files/hk/en/2022-06/2021%20European%20PRRS%20Research%20Award%20winners.png)
September 23, 2021
2021 European PRRS Research Award winners announced
![获得以推进癌症免疫学研究](/sites/default/files/hk/en/2022-07/shutterstock_274014893_0.jpg)
September 21, 2021
Acquisition to advance cancer immunology research
![与安进就KRAS进行临床合作](/sites/default/files/hk/en/2022-07/WebsiteCard.jpg)
September 16, 2021
Clinical collaboration with Amgen on KRAS
![联合使用Ingelvac CircoFLEX®和Ingelvac PRRSFLEX EU®的积极意见 联合使用Ingelvac CircoFLEX®和Ingelvac PRRSFLEX EU®的积极意见](/sites/default/files/hk/en/2022-06/Brazil_IMG_7057_400.jpg)
September 15, 2021
Positive opinion for combined use of Ingelvac CircoFLEX® and Ingelvac PRRSFLEX EU®
September 13, 2021
FRONTLINE® becomes Brand of the Year 2021-2022
![COVID-19研究中的治疗停止 COVID-19研究中的治疗停止](/sites/default/files/hk/en/2022-06/press-release-holding-image01.jpg)
September 09, 2021
Empagliflozin receives Breakthrough Therapy Designation in U.S. for heart failure with preserved ejection fraction (HFpEF)
![勃林格殷格翰和Twist Bioscience进入治疗性抗体发现合作](/sites/default/files/hk/en/2022-07/press-release-holding-image03.jpg)
September 09, 2021
Boehringer Ingelheim and Twist Bioscience Enter Therapeutic Antibody Discovery Collaboration
![勃林格殷格翰宣布美国国家董事总经理Jean-Michel Boers被任命为PhRMA董事会成员](/sites/default/files/hk/en/2022-06/press-release-holding-image01_1.jpg)
August 27, 2021
Landmark trial demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
![2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展 2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展](/sites/default/files/hk/en/2022-06/Pressebild_Boehringer_Ingelheim.png)
August 03, 2021
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
![press-release-holding-image01](/sites/default/files/hk/en/2022-07/press-release-holding-image01.jpg)
July 26, 2021
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
![2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展 2021年上半年:勃林格殷格翰公司在研发方面取得了根本性进展](/sites/default/files/hk/en/2022-06/248400545-2.jpg)
July 16, 2021
Flood disaster in Germany: donation increased to EUR 1 million
![新型FreVAX™智能手机应用将仔猪疫苗接种提高到另一个水平 新型FreVAX™智能手机应用将仔猪疫苗接种提高到另一个水平](/sites/default/files/hk/en/2022-06/DSC_0499_BIPigSoundTalks_KNAPP_04242019.jpg)
July 13, 2021
New FreVAX™ smartphone application brings piglet vaccination to another level
![press-release-holding-image02](/sites/default/files/hk/en/2022-06/press-release-holding-image02_0.jpg)
July 06, 2021
Breakthrough results for empagliflozin confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
![勃林格殷格翰庆祝在欧洲对抗PRRS 25年 勃林格殷格翰庆祝在欧洲对抗PRRS 25年](/sites/default/files/hk/en/2022-06/Pigs.jpg)
June 30, 2021